Phase III ADVANCE: 96-Wk Primary Efficacy Analysis of DTG + FTC/(TAF or TDF) vs EFV/FTC/TDF in ART-Naive PWH in South Africa

July 6-10, 2020; Virtual
Noninferiority of first-line DTG-based vs EFV-based regimens maintained through Week 96, with significantly greater weight gain observed in PWH receiving DTG + FTC/TAF.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Clinical Care Options (CCO): woman’s perspective on her struggle with HIV stigma and why volunteering to help others with HIV has become her purpose

person default Anonymous Patient Released: January 10, 2022

Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 5, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings